Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma Statistics

Total Valuation

Nuvectis Pharma has a market cap or net worth of $162.92 million. The enterprise value is $136.64 million.

Market Cap	162.92M
Enterprise Value	136.64M

Important Dates

The next estimated earnings date is Tuesday, November 4, 2025, before market open.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Nuvectis Pharma has 25.46 million shares outstanding. The number of shares has increased by 16.00% in one year.

Current Share Class	25.46M
Shares Outstanding	25.46M
Shares Change (YoY)	+16.00%
Shares Change (QoQ)	+7.17%
Owned by Insiders (%)	42.90%
Owned by Institutions (%)	14.01%
Float	14.54M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	8.76
P/TBV Ratio	9.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.66

Current Ratio	2.66
Quick Ratio	2.64
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -150.12% and return on invested capital (ROIC) is -97.67%.

Return on Equity (ROE)	-150.12%
Return on Assets (ROA)	-63.38%
Return on Invested Capital (ROIC)	-97.67%
Return on Capital Employed (ROCE)	-136.15%
Revenue Per Employee	n/a
Profits Per Employee	-$1.70M
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.41% in the last 52 weeks. The beta is -0.28, so Nuvectis Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.28
52-Week Price Change	-2.41%
50-Day Moving Average	6.91
200-Day Moving Average	7.46
Relative Strength Index (RSI)	49.23
Average Volume (20 Days)	59,318

Short Selling Information

The latest short interest is 982,835, so 3.86% of the outstanding shares have been sold short.

Short Interest	982,835
Short Previous Month	1.02M
Short % of Shares Out	3.86%
Short % of Float	6.76%
Short Ratio (days to cover)	8.25

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-22.97M
Pretax Income	-21.10M
Net Income	-22.07M
EBITDA	n/a
EBIT	-22.97M
Earnings Per Share (EPS)	-$1.16

Balance Sheet

The company has $26.79 million in cash and n/a in debt, giving a net cash position of $26.79 million or $1.05 per share.

Cash & Cash Equivalents	26.79M
Total Debt	n/a
Net Cash	26.79M
Net Cash Per Share	$1.05
Equity (Book Value)	16.87M
Book Value Per Share	0.71
Working Capital	16.87M

Cash Flow

Operating Cash Flow	-12.41M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nuvectis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.00%
Shareholder Yield	-16.00%
Earnings Yield	-13.50%
FCF Yield	n/a

Analyst Forecast

The average price target for Nuvectis Pharma is $15.33, which is 139.53% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$15.33
Price Target Difference	139.53%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1